All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-07-05T13:19:43.000Z

Key challenges and best practice recommendations in pregnant patients with MPN

By Marcia Rato, Erika Roa, Ella Dixon
Featured
Claire Harrison
Jul 5, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in rare MPN and MPN in special populations.

Bookmark this article

The MPN Hub was pleased to speak to Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked, what are the key challenges and best practice recommendations in pregnant patients with myelodysplastic syndromes (MPN)?

Key challenges and best practice recommendations in pregnant patients with MPN

Harrison begins by discussing why pregnancy can cause problems in patients with MPN, and which types of MPN are most common in these patients. Harrison also discusses the importance of planning pregnancy in advance, and the use of anticoagulants.

More about...
AnticoagulantsDiagnostic and treatment guidelinesSpecial populations

Your opinion matters

HCPs, what is your preferred format for educational content on the MPN Hub?
19 votes - 79 days left ...

Related articles

Add bookmark

The future of JAK inhibition in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas...

Jul 22, 2022
Add bookmark

The future of JAK inhibition in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in...

Jul 22, 2022
Add bookmark

Treatment sequencing in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about treatment sequencing in myelofibrosis. The session was chaired by Jean-Jacques Kiladjian and...

Jul 20, 2022
Add bookmark

Treatment sequencing in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about treatment sequencing in myelofibrosis. The...

Jul 20, 2022
Add bookmark

Best practice recommendations for the management of MPN in pregnant patients

The management of myeloproliferative neoplasms (MPN) in pregnant patients generates a distinctive set of patient and fetal challenges. Here, we summarize two publications...

Jun 22, 2022
Add bookmark

Best practice recommendations for the management of MPN in pregnant patients

The management of myeloproliferative neoplasms (MPN) in pregnant patients generates a distinctive set of patient and fetal...

Jun 22, 2022
Add bookmark

Patient follow-up in myeloproliferative neoplasms: Best practices and myths

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of Wisconsin, Milwaukee, US) and Claire Harrison...

Feb 4, 2022
Add bookmark

Patient follow-up in myeloproliferative neoplasms: Best practices and myths

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of...

Feb 4, 2022

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox